Metabolik İlişkili Steatotik Karaciğer Hastalığında (MASLD) Güncel Tedavi Yaklaşımları

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obesity Facts. 2024;17:374-444.

Sheikh M, Younus M, Shergill A, Hasan M. Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review. International Journal of Molecular Sciences. 2025;26.

Jurek J, Zablocka-Sowinska K, Mestres H, et al. The Impact of Dietary Interventions on Metabolic Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Comorbid Conditions, Including Obesity and Type 2 Diabetes. Nutrients. 2025;17.

Hwang J, Hwang H, Shin H, et al. Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis. Clinical and Molecular Hepatology. 2024;30:561-576.

Emanuele F, Biondo M, Tomasello L, et al. Ketogenic Diet in Steatotic Liver Disease: A Metabolic Approach to Hepatic Health. Nutrients. 2025;17.

Palumbo P, Di Betto G, Menozzi R, et al. Pros and cons of different dietary patterns for the treatment of metabolic dysfunction-associated steatotic liver disease. Metabolism: clinical and experimental. 2025:156425.

Drygalski K. Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences. 2025;26.

Wang Y, Zhou Y, Wang Z, et al. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. The Journal of clinical endocrinology and metabolism. 2025.

Nowak K, Łupina K, Romac A, et al. Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease. Annals of Pharmacotherapy. 2025;59:928-936.

Henney A, Riley D, Anson M, et al. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver International. 2025;45.

Targher G, Byrne C, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.

Noureddin N, Copur-Dahi N, Loomba R. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease. Alimentary Pharmacology & Therapeutics. 2024;59:S41-S51.

Shah A, Mohammadi A, Haq A, et al. Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes. Obesity Surgery. 2025;35:4508-4517.

Pereira L, De Barros F, De Andrade T, et al. METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE ASSESSMENT OF PATIENTS WITH OBESITY AND METABOLIC SYNDROME GUIDELINE FROM THE BRAZILIAN SOCIETY OF BARIATRIC AND METABOLIC SURGERY. Arquivos Brasileiros de Cirurgia Digestiva: ABCD. 2024;37.